The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Open accessAbstract
HDL is a major atheroprotective factor, but the mechanisms underlying this effect are still obscure. HDL binding to scavenger receptor-BI has been shown to activate eNOS, although the responsible HDL entities and signaling pathways have remained enigmatic. Here we show that HDL stimulates NO release in human endothelial cells and induces vasodilation in isolated aortae via intracellular Ca2+ mobilization and Akt-mediated eNOS phosphorylation. The vasoactive effects of HDL could be mimicked by three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF). All three elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation. Deficiency of the lysophospholipid receptor S1P3 (also known as LPB3 and EDG3) abolished the vasodilatory effects of SPC, S1P, and LSF and reduced the effect of HDL by approximately 60%. In endothelial cells from S1P3-deficient mice, Akt phosphorylation and Ca2+ increase in response to HDL and lysophospholipids were severely reduced. In vivo, intra-arterial administration of HDL or lysophospholipids lowered mean arterial blood pressure in rats. In conclusion, we identify HDL as a carrier of bioactive lysophospholipids that regulate vascular tone via S1P3-mediated NO release. This mechanism may contribute to the vasoactive effect of HDL and represent a novel aspect of its antiatherogenic function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 9×
“To test whether G protein– coupled receptor signaling by HDL and HDL-associated lysophospholipids is involved in their effects on NO generation and vasodilation, we preincubated HUVECs with pertussis toxin (PTX), an irreversible Gi activation blocker, prior to stimulation with HDL, SPC, S1P, and LSF. PTX (100 ng/ml) a…”
BackgroundInfluentialRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608
Lee, M.-J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha'afi, R. I., & Hla, T. (1999) · Cell · doi:10.1016/s0092-8674(00)81661-x · Cited by 1,013
Michiels, C. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10333 · Cited by 773
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Self-citationYuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L. D., Osborne-Lawrence, S., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 742
Zachary, I. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00268-6 · Cited by 662
Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis
Loscalzo, J. (2001) · Circulation Research · doi:10.1161/hh0801.089861 · Cited by 612 · cited 3×
“roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis.”
Background
Cited by
Nathan, C., & Ding, A. (2010) · Cell · doi:10.1016/j.cell.2010.02.029 · Cited by 2,183
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 655
Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 647
HDL Cholesterol and Protective Factors in Atherosclerosis
Assmann, G., & Gotto, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000131512.50667.46 · Cited by 630
Self-citationEndothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnström, J., Sevvana, M., Egerer-Sieber, C., Muller, Y. A., Hla, T., Nielsen, L. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103187108 · Cited by 598
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response
Murphy, A. J., Woollard, K. J., Hoang, A., Mukhamedova, N., Stirzaker, R. A., McCormick, S. P. A., Remaley, A. T., Sviridov, D., & Chin-Dusting, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.168690 · Cited by 508
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Biological activities of HDL subpopulations and their relevance to cardiovascular disease
Camont, L., Chapman, M. J., & Kontush, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.013 · Cited by 471
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., Thomas, W. G., Mukhamedova, N., de Courten, B., Forbes, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843219 · Cited by 443
Tall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
THE REGULATION AND PHARMACOLOGY OF ENDOTHELIAL NITRIC OXIDE SYNTHASE
Dudzinski, D. M., Igarashi, J., Greif, D., & Michel, T. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121844 · Cited by 425
Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schäfers, M., Herrgott, I., Mersmann, J., Larmann, J., Hermann, S., Stypmann, J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.607135 · Cited by 416
Self-citationSorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402
Unraveling the complexities of the HDL lipidome
Kontush, A., Lhomme, M., & Chapman, M. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036095 · Cited by 396
Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism
Meyer zu Heringdorf, D., & Jakobs, K. H. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.026 · Cited by 388
Thomas, S. R., Witting, P. K., & Drummond, G. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2027 · Cited by 383
“The beneficial actions of HDL may relate, in part, to lipid factors that associate with the lipoprotein, including sphingosine 1-phosphate (376) and estrogen (181), which activate eNOS in endothelial cells.”
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330
Self-citationGalvani, S., Sanson, M., Blaho, V. A., Swendeman, S. L., Obinata, H., Conger, H., Dahlbäck, B., Kono, M., Proia, R. L., Smith, J. D., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa2581 · Cited by 314
Speer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 291
Targeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
Seetharam, D., Mineo, C., Gormley, A. K., Gibson, L. L., Vongpatanasin, W., Chambliss, K. L., Hahner, L. D., Cummings, M. L., Kitchens, R. L., Marcel, Y. L., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000199272.59432.5b · Cited by 285
Sphingolipids in inflammation: pathological implications and potential therapeutic targets
Nixon, G. F. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00281.x · Cited by 285
Sphingosine Kinase: Biochemical and Cellular Regulation and Role in Disease
Taha, T. A., Hannun, Y. A., & Obeid, L. M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.2.113 · Cited by 276
HDL cholesterol: reappraisal of its clinical relevance
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1106-1 · Cited by 275
“Many of the endothelial effects of HDL are mediated by the endothelial SR-B1 receptor and by the bioactive lipid sphingosine-1-phosphate that can act via the S1P3 receptor on endothelial cells [54].”
BackgroundChapman, M. J., Assmann, G., Fruchart, J.-C., Shepherd, J., & Sirtori, C. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Self-citationLysophospholipids and their receptors in the central nervous system
Choi, J. W., & Chun, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.015 · Cited by 255
Self-citationObesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
“The beneficial properties of HDL on the endothelium include vasodilatory activity, primarily through stimulation of nitric oxide (NO) release from endothelial cells [40,54], and also the production of prostacyclin [55,56].”
BackgroundCurrent understanding of the metabolism and biological actions of HDL
Eckardstein, A. V., Hersberger, M., & Rohrer, L. (2005) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200503000-00007 · Cited by 155
The clinical significance of endothelial dysfunction
Landmesser, U., & Drexler, H. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000179821.11071.79 · Cited by 142
Soucy, K. G., Ryoo, S., Benjo, A., Lim, H. K., Gupta, G., Sohi, J. S., Elser, J., Aon, M. A., Nyhan, D., Shoukas, A. A., et al. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00138.2006 · Cited by 135
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient
Yanagida, K., & Hla, T. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071635 · Cited by 109
Annema, W., & von Eckardstein, A. (2016) · Translational Research · doi:10.1016/j.trsl.2016.02.008 · Cited by 94
Okon, E. B., Chung, A. W. Y., Zhang, H., Laher, I., & van Breemen, C. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-026 · Cited by 50
Inflammation, high-density lipoprotein and cardiovascular dysfunction
Haas, M. J., & Mooradian, A. D. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328344b724 · Cited by 38
Ishii, T., Shimazu, Y., Nishiyama, I., Kikuta, J., & Ishii, M. (2011) · Molecules and Cells · doi:10.1007/s10059-011-1010-x · Cited by 32
Metadata
- Authors
- Nofer, J.-R., van der Giet, M., Tölle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H. A., Tietge, U. J., Gödecke, A., Ishii, I., Kleuser, B., Schäfers, M., Fobker, M., Zidek, W., Assmann, G., Chun, J., & Levkau, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 569-581
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2138137064
- Cited by
- 698
- References
- 53
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.